Nycomed loses out in Solvay bid
Abbot Laboratories stepped in to buy the Eu4.5bn pharmaceutical unit of Solvay on Monday night, scuppering a potential leveraged financing for private equity-backed Nycomed.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
